MedTrace Logo

Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites

NCT07257627 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-12-02

No results posted yet for this study

Summary

This open-label, randomized, three-period crossover, 8-hour hyperinsulinemic-euglycemic clamp study will compare the pharmacokinetic and pharmacodynamic profiles of THDB0206 after single subcutaneous administration at different injection sites in healthy Chinese adults.

Conditions

  • Healthy Participants

Interventions

DRUG

THDB0206 Injection-Thigh

Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the thigh.

DRUG

THDB0206 injection-Upper arm

Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the upper arm.

DRUG

THDB0206 Injection-Abdomen

Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the abdomen.

Sponsors & Collaborators

  • Tonghua Dongbao Pharmaceutical Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2024-12-02
Completion
2024-12-02

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07257627 on ClinicalTrials.gov